GeNeuro SA
GNRO
Company Profile
Business description
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
Contact
3 chemin du Pre-Fleur
Plan-les-Ouates
Geneva1228
CHET: +41 225524800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,341.00 | 53.10 | 0.64% |
| CAC 40 | 7,542.48 | 13.39 | -0.18% |
| DAX 40 | 22,324.29 | 101.54 | -0.45% |
| Dow JONES (US) | 39,923.97 | 603.65 | -1.49% |
| FTSE 100 | 8,448.40 | 15.06 | -0.18% |
| HKSE | 22,119.41 | 111.30 | 0.51% |
| NASDAQ | 17,083.02 | 378.29 | -2.17% |
| Nikkei 225 | 36,045.38 | 205.39 | 0.57% |
| NZX 50 Index | 11,903.31 | 122.14 | -1.02% |
| S&P 500 | 5,464.33 | 96.50 | -1.74% |
| S&P/ASX 200 | 8,126.20 | 55.60 | 0.69% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |